HEОбмен на изследователи2022–2027

MX-MAP · Towards MXenes’ biomedical applications by high-dimensional immune MAPping

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период
2022-11-01 → 2027-04-30
Финансиране от ЕС
1 389 200 €
Участници
16
Схема
HORIZON-TMA-MSCA-SE

Линиите свързват координатора с партньорите.

Накратко на български

Двуизмерните наноматериали, наречени максени, се изследват за приложения в медицината, като например при насочено доставяне на лекарства или лечение на рак. Това помага да се разбере как имунната система реагира на тези материали, за да се използват безопасно в терапиите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Towards MXenes’ biomedical applications by high-dimensional immune MAPping

The MX-MAP project is an innovative initiative addressing global health challenges by leveraging the unique properties of two-dimensional (2D) nanomaterials, specifically MXenes, for biomedical applications. Collaborating across leading academic and industrial partners from Europe, North America, and Asia, MX-MAP integrates interdisciplinary expertise to bridge critical gaps in MXene biocompatibility and immune interactions. The project aims to develop a functional pipeline for MXene immune characterization, enabling their safe use in therapies such as cancer photothermal/photodynamic treatments, regenerative medicine, targeted drug delivery, and antibacterial strategies. By advancing material synthesis, functionalization, and characterization, MX-MAP drives research excellence while fostering the next generation of researchers through hands-on training and collaboration. The outcomes—scalable MXene production, immune profiling tools, and novel therapeutic applications—will contribute to Europe’s strategic priorities in healthcare innovation, positioning the EU as a leader in nanotechnology and biomedical research while improving global health outcomes.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The long-term goal of MX-MAP is to develop a functional pipeline for the immune characterization of new 2D nanomaterials of MXene family, for the qualitative and quantitative assessment of the human immune compatibility and immune activity towards biomedical applications.The immune characterization of the tested materials on the basis of intrinsic physical-chemical and immunological properties, through the combination of the most innovative technologies such as single-cell mass cytometry (CyTOF), will open breakthrough perspectives for the development of new therapeutic approaches applying nanomaterials as immunomodulators, scaffolds for tissue engineering, cancer therapy, and antibacterial agents. MX-MAP will develop key chemistry and immune-based strategies for MXene medical applications. The implication of this project extends beyond the specific nanoscience program greatly advancing the engineering process of 2D materials and their use in biomedicine.The MX-MAP project involves fourteen key players in European and non-European countries, including the United States, Canada, Saudi Arabia, and three partners from Ukraine, coming from academia and SMEs. This program will provide strong support for the development of the careers of young brilliant scientists who want to grow towards an interdisciplinary vision of Science. Chemistry, biology, immunology, engineering, and cancer research are the expertise of MX-MAP. The senior team members are among the most influential scientists, including Prof. Yury Gogotsi (H-index=168) - inventor of MXenes, Prof. Klaus Ley (H-index=147) - one of the most cited immunologists worldwide, and Prof. Husam N Alshareef (H-index=99). The Consortium is perfectly balanced in terms of equal gender presence; the project Coordinator Lucia Gemma Delogu is a female, and 2 out 4 of four WP leaders are female. The project embraces a large view of inclusiveness and diversity, including countries with smaller economies such as Ukraine.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз